Izrael - héber - Ministry of Health

sanofi israel ltd - dupilumab - תמיסה להזרקה - dupilumab 175 mg/ml - dupilumab

Izrael - héber - Ministry of Health

sanofi israel ltd - isatuximab - תרכיז להכנת תמיסה לאינפוזיה - isatuximab 20 mg / 1 ml - isatuximab

Izrael - héber - Ministry of Health

sanofi israel ltd - insulin aspart - תמיסה להזרקה - insulin aspart 100 u/ml - insulin aspart

Izrael - héber - Ministry of Health

sanofi israel ltd - alemtuzumab - תרכיז להכנת תמיסה לאינפוזיה - alemtuzumab 12 mg / 1.2 ml - alemtuzumab

Izrael - héber - Ministry of Health

sanofi israel ltd - glimepiride - טבליה - glimepiride 1 mg - glimepiride - glimepiride - non-insulin-dependent diabetes melitus ( adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

Izrael - héber - Ministry of Health

sanofi israel ltd - glimepiride - טבליה - glimepiride 2 mg - glimepiride - glimepiride - non-insulin-dependent diabetes melitus ( adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

Izrael - héber - Ministry of Health

sanofi israel ltd - glimepiride - טבליה - glimepiride 3 mg - glimepiride - glimepiride - non-insulin-dependent diabetes melitus ( adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

Izrael - héber - Ministry of Health

sanofi israel ltd - glimepiride - טבליה - glimepiride 4 mg - glimepiride - glimepiride - non-insulin-dependent diabetes melitus ( adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

Izrael - héber - Ministry of Health

sanofi israel ltd - enoxaparin sodium - תמיסה להזרקה - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - enoxaparin sodium is an anti-coagulant. at dosesof 20 mg and 40 mg it is indicated for: - prophylactic treatment of thrombo-embolic disorders of venous origin and in particular in orthopedic surgery or in general surgery. - prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. at dosege of 40 mg the indications are: - prophylactic treatment of deep vein thrombosis in patients who are bedridden due to an acute medial disorder: - heart failure (hyha class iii or iv) - acute respiratory failure - episode of acute infection or acute rheumatic disorder combined with at least one other venous thromboembolic risk factor. at high doses of 60, 80 ,100 mg clexan is indicated for: -treatment of deep vein thrombosis (dvt). - treatment of unstable angina and non-q-wave myocardial infaction administered concurrently with aspirin. - treatment of pulmonary embolism.treatment of acute st- segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible o

Izrael - héber - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid